Ryan O’Keefe: Diagnostic Insights Into High-Risk Myelodysplastic Syndrome
Ryan O’Keefe, Internal Medicine Resident at the Hospital of The University of Pennsylvania, Creator of Point of Care Medicine, shared a post on X:
“Daily Pearl(s):
High-Risk Myelodysplastic Syndrome (MDS) with U2AF1 Mutation.
The triad of unexplained systemic inflammation (high ESR/CRP), progressive cytopenias, and an opportunistic infection (such as candida esophagitis) should raise suspicion for an underlying hematologic malignancy like MDS.
In complex cases with multiple problems, systematically evaluate each one before attempting to unify them – pursuing a red herring as part of a systemic process can be dangerously misleading.
Bilateral adrenal hemorrhage is a medical emergency and can be a rare paraneoplastic manifestation of MDS, which creates a paradoxical state of thrombosis (from inflammation) and hemorrhage (from thrombocytopenia).
Clonal hematopoiesis (MDS, VEXAS syndrome) is an increasingly recognized cause of severe seronegative or atypical autoimmune and vasculitic syndromes, particularly in older adults.
When persistent, unexplained cytopenias and systemic illness remain after extensive infectious and rheumatologic workups, bone marrow biopsy with genetic testing can be a critical diagnostic step.
MDS impairs innate immune function, predisposing patients to opportunistic fungal infections even without classic risk factors like chemotherapy or high-dose steroids.
High-risk MDS is treated with hypomethylating agents (azacitidine) or, in eligible patients, allogeneic stem cell transplantation.
Spliceosome mutations (U2AF1, SF3B1, SRSF2) and UBA1 mutations (VEXAS) are key driver variants to know.
Source: April 11, 2026 Simplicity in Complexity VMR with Jeffrey and Kirtan – dyspnea and vision loss.”
Stay updated with Hemostasis Today.
-
Jun 30, 2026, 15:33Francois Delvoye: Thrombo-Inflammation and NETs May Represent the Next Therapeutic Frontier in SAH
-
Jun 30, 2026, 15:23The DETECT-VTE Study Reminds Us That VTE Doesn’t Always Look Typical – RPTH
-
Jun 30, 2026, 15:20Heghine Khachatryan: New Insights on Thrombosis in BCR-ABL1 Negative Myeloproliferative Neoplasms
-
Jun 30, 2026, 15:17Fayad Al-Haimus: CAEP–CanVECTOR Research Grant Backs Pulmonary Embolism Study
-
Jun 30, 2026, 15:03Hugo Ribeiro: Republished Paper Highlights Folic Acid and Iron Supplementation in Anemia
-
Jun 30, 2026, 14:40A Patient-Centered Approach on Hormone Therapy Following Thrombosis – Thrombosis Canada
-
Jun 30, 2026, 14:32Lindsey George: Blood Study Links AAV-Derived FVIII Activity to Clinical Outcomes
-
Jun 30, 2026, 10:01Robert Lufkin: Stop Eating 3 Hours Before Bed
-
Jun 30, 2026, 09:52Kathleen Freson: Opportunities to Lead Thrombosis and Hemostasis in ISTH